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Abstract
Background: Artemisinin-based combination therapy is currently recommended by the World Health Organization
as first-line treatment of uncomplicated malaria. Recommendations were adapted in 2010 regarding rescue
treatment in case of treatment failure. Instead of quinine monotherapy, it should be combined with an antibiotic
with antimalarial properties; alternatively, another artemisinin-based combination therapy may be used. However,
for informing these policy changes, no clear evidence is yet available. The need to provide the policy makers with
hard data on the appropriate rescue therapy is obvious. We hypothesize that the efficacy of the same artemisinin-
based combination therapy used as rescue treatment is as efficacious as quinine + clindamycin or an alternative
artemisinin-based combination therapy, without the risk of selecting drug resistant strains.
Design: We embed a randomized, open label, three-arm clinical trial in a longitudinal cohort design following up
children with uncomplicated malaria until they are malaria parasite free for 4 weeks. The study is conducted in both
the Democratic Republic of Congo and Uganda and performed in three steps. In the first step, the pre-randomized
controlled trial (RCT) phase, children aged 12 to 59 months with uncomplicated malaria are treated with the
recommended first-line drug and constitute a cohort that is passively followed up for 42 days. If the patients
experience an uncomplicated malaria episode between days 14 and 42 of follow-up, they are randomized either to
quinine + clindamycin, or an alternative artemisinin-based combination therapy, or the same first-line artemisinin-
based combination therapy to be followed up for 28 additional days. If between days 14 and 28 the patients
experience a recurrent parasitemia, they are retreated with the recommended first-line regimen and actively
followed up for another 28 additional days (step three; post-RCT phase). The same methodology is followed for
each subsequent failure. In any case, all patients without an infection at day 28 are classified as treatment successes
and reach a study endpoint. The RCT phase allows the comparison of the safety and efficacy of three rescue
treatments. The prolonged follow-up of all children until they are 28 days parasite-free allows us to assess
epidemiological-, host- and parasite-related predictors for repeated malaria infection.
Trial registration: NCT01374581 and PACTR201203000351114
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Background
Malaria remains one of the great infectious killers in Africa.
An estimated 300 to 500 million cases occur each year, caus-
ing 1.5 to 2.7 million deaths, primarily in children under the
age of 5 years [1]. The reduction of malaria-associated mor-
bidity and mortality relies largely on chemotherapy. Consid-
ering these facts, for the foreseeable future the major
intervention available for the control of malaria (and a key
Roll Back Malaria priority) remains the prompt treatment of
symptomatic malaria with effective therapy. However, the
success of this strategy has been greatly affected by the in-
creasing resistance of malaria parasites to available drugs.
This results in increased progression of disease from un-
complicated to complicated forms, and increased mortality
[2]. Therefore, choices of the best treatment for uncompli-
cated malaria in Africa have become increasingly complex.
Following the World Health Organization (WHO) guide-
lines, most African countries have already opted for
artemisinin-based combination therapy (ACT). Several clin-
ical trials on artesunate-amodiaquine (ASAQ), an ACT,
completed in Africa have shown an efficacy >90% [3-6].
Furthermore, after PCR analysis, over 75% of ASAQ and
artemether-lumefantrine (AL) treatment failures have been
classified as new infections, while recrudescences have low
parasite densities [6]. ASAQ is safe and easy administered,
with a good treatment adherence [3-5]. Therefore, effective-
ness may be close to efficacy. ASAQ has now been devel-
oped as a fixed-dose combination and registered. The
Democratic Republic of Congo (DRC) has chosen ASAQ
as first-line treatment for uncomplicated malaria. Efficacy
of the six-dose regimen of AL has been demonstrated in
semi-immune and non-immune populations in Asia and
Africa to be consistently greater than 95%, with rapid para-
site and symptom clearance and significant gametocytocidal
effect [7]. In Uganda, AL has been chosen as first-line treat-
ment for uncomplicated malaria.
In DRC and Uganda, quinine is the rescue treatment for
malaria. It is cheap, widely available and generally consid-
ered to be effective but is not popular due to its side ef-
fects. Quinine has a very short half-life; therefore, repeated
dosing is required. In an efficacy study of quinine and arte-
misinin for uncomplicated malaria in Vietnam, recrudes-
cence rates were 16% after 7 days of quinine monotherapy
[8]. In studies conducted in Gabon, neighbouring DRC,
Plasmodium falciparum in vitro sensitivity to quinine was
high and had not changed over the past decade [9]. Al-
though quinine monotherapy shows high efficacy in the
setting of clinical trials, it has considerable disadvantages,
mainly because of its poor tolerability and the prolonged
treatment course. Poor adherence carries a high risk of
treatment failure, particularly because quinine causes a syn-
drome of adverse effects known as cinchonism that includes
primarily tinnitus, nausea, and vertigo. Other reported side
effects are high tone hearing impairment, dizziness, and
hypotension as well as headache and visual disturbances
[10]. As a result of these side effects, some studies have
reported poor compliance to treatment. A randomized
trial in Thailand reported 71% adherence. Such poor ad-
herence to the 7-day regimen is associated with a high
risk of treatment failure [11], which can contribute to
the development and spread of resistance [10]. Further-
more, in current practices, patients are often retrea-
ted with the recommended first-line drug. As quinine
is effective against all species of malaria, including
chloroquine-resistant strains of P. falciparum, it remains an
important drug for severe malaria, although the current
trend is to replace this with intravenous artesunate, which
in some settings has already occurred whilst in others it is
currently happening. Therefore, quinine should be protected
from resistance by rational use, as its effectiveness in
uncomplicated malaria is lower than ACT [12].
Potential selection of resistant strains
This study aims to assess the possible impact of using the
same first-line treatment as rescue treatment. Furthermore,
as part of the study protocol, mutations in the P. falciparum
multidrug resistance (pfmdr)1 will be analyzed in order to
evaluate the potential risk of selecting drug-resistant strains.
The longitudinal, continued follow-up of all treatment fail-
ures will additionally enable host-, environmental- and
parasite-related predictors of recurrent, recrudescent or re-
infections to be identified.
Rationale
Considering the facts that (i) over >75% of treatment failure
to ASAQ or AL are new infections, (ii) parasite density is
low in case of recrudescence occurring from day 14 onwards,
and (iii) in real-life situations patients are retreated with the
same first-line drug, there is a need to assess the role of the
first-line treatment as rescue treatment. This efficacy will be
compared to quinine + clindamycin and another ACT treat-
ment in line with the WHO guideline [13]. We hypothesize
that retreatment with the first-line ACT treatment beyond
14 days is as efficacious as any other rescue treatment, with-
out the risk of selecting drug-resistant strains. Furthermore,
a prolonged follow-up will enable the assessment of the
host-related, parasite-related and environmental risk factors
for repeated malaria infection. Therefore, we will collect
dried samples and serum samples for analyzing (that is, im-
munological and molecular biological assessment).
Trial objectives
Efficacy
The primary objectives are: (1) to show that, in children
aged 12 to 59 months with recurrent uncomplicated
P. falciparum malaria within 42 days of treatment with
an ACT (ASAQ in DRC or AL in Uganda), the PCR ad-
justed efficacy at 28 days after retreatment with the
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same artemisinin-based combination therapy is at least
90%; and (2) to estimate the relative efficacy of retrea-
tment with the same ACT compared to treatment with
quinine + clindamycin and treatment with an alterna-
tive ACT (ASAQ after first-line AL treatment or AL
after first-line ASAQ treatment).
Secondary objectives are: (1) to evaluate the PCR-
unadjusted efficacy at 28 days of retreatment with the
same ACT and to compare it to treatment with quinine +
clindamycin and treatment with another ACT (ASAQ
after first-line AL treatment or AL after first-line ASAQ
treatment); (2) to evaluate and compare the efficacy of AL,
ASAQ and quinine + clindamycin as rescue treatment for
a recurrent P. falciparum malaria episode occurring 2
weeks after the administration of the first-line treatment,
with and without PCR adjustment; (3) to evaluate and
compare the 42-day clinical efficacy of AL (Uganda) and
ASAQ (DRC) for the first-line treatment of uncomplicated
P. falciparum malaria, with and without PCR adjustment;
and (4) to evaluate and compare the efficacy of the differ-
ent rescue treatment regimens in terms of fever clearance
time, asexual parasite clearance time, gametocytemia at
days 7, 14, 21 and 28, and hemoglobin changes between
day 0 and days 14 and 28.
Additional objectives are: (1) to evaluate transcriptional
changes and selection of P. falciparum pfmdr1 and other al-
leles following therapy with quinine + clindamycin, AL and
ASAQ; and (2) to assess epidemiological-, parasitological-
and host-related predictors (including genetic factors) for
recurrent malaria infections (adjacent studies will be devel-
oped in separate nested-study protocols).
Safety
To evaluate the safety and tolerability of AL, ASAQ and
quinine + clindamycin when used as rescue treatments.
Drugs to be tested
Quinine + clindamycin
Quinine is an alkaloid from the bark of the cinchona tree
that still constitutes one of the major components of the
antimalarial pharmacopeia, as it has for over three centur-
ies. Quinine is still widely used for the treatment of severe
malaria and serves in oral formulation as a reserve drug for
uncomplicated malaria, mostly in combination with a tetra-
cycline or doxycycline or clindamycin. It is effective against
all species of malaria including chloroquine-resistant strains
of P. falciparum. Quinine belongs to the aryl amino alcohol
group of drugs. It is a cinchona alkaloid that has a rapid
schizonticidal action on the intra-erythrocytic parasites and
is also gametocytocidal for P. vivax and P. malariae but not
for P. falciparum.
In DRC, quinine + clindamycin is the second-line treat-
ment for malaria. In Uganda, quinine is the rescue treat-
ment, but a combination with clindamycin might be
expected in the near future. Quinine is cheap, widely avail-
able and generally considered to be effective though it is
not popular due to the unwanted side effects. Quinamax®
is a formulation developed by Sanofi-Aventis (Paris,
France) which comprises four alkoloids: quinine, quini-
dine, cinchonin and cinchonidine. In this study, we use
dry tablets (125 mg) with no dosage adaptation for chil-
dren below 9 kg (which explains why children below 12
months are excluded from our study).
Clindamycin is a lincosamide antibiotic derivative of
lincomycin. It is very soluble in water. It inhibits the
early stages of protein synthesis by a mechanism similar
to that of the macrolides. It may be administered by
mouth as capsules containing the hydrochloride or as oral
liquid preparations containing the palmitate hydrochloride.
Clindamycin is used twice daily for at least 5 days at 10
mg/kg for children aged 11 years and under. Clindamycin
used in combination with quinine is safe but limited data
have so far been gathered [14]. In this study, we use
clindamycin from Pfizer (New York City, the United States
of America) marketed under the brand name of Dalacin®.
Artemether-lumefantrine
This is a fixed-dose combination of artemether (a semi-
synthetic artemisinin derivative) and lumefantrine (a
slowly eliminated drug also referred to as benflumetol).
The registered indications and branding for AL cover
treatment of uncomplicated malaria caused by mono or
mixed Plasmodium infections. The combination is expected
to confer mutual protection against resistance and prevent
recrudescence after artemether therapy. The components of
this combination were originally studied and developed in
China by the Academy of Military Medical Sciences (Beijing
and Kunming Pharmaceutical Factory, Kunming). The fixed
combination has been registered in China since 1992 and
has undergone further development when Novartis (Basel,
Switzerland) signed a collaborative agreement in 1994 with
the Academy of Military Medical Sciences and CITITEC,
the technology arm of the China International Trust and
Investment Corporation (Beijing, China). Studies for
the international registration started in 1995. AL from
Novartis, marketed under the trademarks Riamet® and
Coartem®, was registered in Switzerland in 1999. It is
prequalified by WHO and has since received marketing
authorization in several endemic and non-endemic coun-
tries. A recent review showed that the drug combination
is highly efficacious against sensitive and multidrug re-
sistant falciparum malaria as it offers the advantage of
rapid clearance of parasites by artemether and the slower
elimination of residual parasites by lumefantrine [7].
Artesunate-amodiaquine
ASAQ (co-formulated as Co-arsucam® or ASAQ Winthrop®;
Sanofi-Aventis (Paris, France) is safe, easy to use and
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efficacious, and the second most used ACT worldwide
[5,6]. DRC, through the National Malaria Control Pro-
gram, has complied with the WHO recommendation by
recommending ASAQ as first-line treatment since 2005
for uncomplicated malaria. In a study conducted in 2004
in the eastern part of the country, the efficacy of ASAQ
was estimated at 93% after PCR adjustment [4]. Twenty
five trials (11,700 patients) carried out in Sub-Saharan
Africa show a PCR-adjusted efficacy at day 28 of 94%
[6]. A study has been conducted in Burkina Faso in chil-
dren under 5 years of age and has shown that co-
formulated ASAQ is well tolerated and its efficacy was
93% after PCR correction [5]. We use co-formulated
ASAQ Winthrop® (Sanofi-Aventis), dosed by age, and
put on the market in March 2007. This product has
been prequalified by WHO.
Study design
This is a bi-centre, phase IIIb, randomized, open label,
three-arm trial. It is performed in three steps (Figure 1)
and there is informed consent for the first two steps.
Study phases
Pre-randomized controlled trial phase
All patients are treated with the first-line treatment -
ASAQ for DRC and AL for Uganda. Before treatment, a
blood sample is collected on filter paper (Whatman 3MM,
Maidstone England) for subsequent parasite genotyping. A
serum sample is also collected and frozen for further im-
munological assessment (adjacent study). Patients are pas-
sively followed up for the next 42 days. During this period,
no systematic screening for malaria infection is done. In-
stead, blood samples are collected only for patients attend-
ing the health facilities with suspected clinical malaria. In
case of confirmed failure before day 14, patients are treated
with quinine + clindamycin and excluded from the follow-
up as they have reached one of the endpoints. Patients ex-
periencing a clinical failure (fever and parasitemia with any
parasite density) between days 14 and 42 are eligible for
the second phase. The day of failure corresponds to day 0
of the following phase. Patients are assessed as summarized
in Additional file 1.
Randomized controlled trial phase
This step constitutes the core of the study. After the second
informed consent (that covers also the post-RCT phase),
patients are randomly assigned to ASAQ, AL or quinine +
clindamycin. Rescue treatment allocation is concealed until
the recruitment of the patient in the RCT phase. The
randomization list was generated prior to the beginning of
the study by the study statistician. At the study site, treat-
ment allocation and administration of medications are
performed by the study physician or nurse. Patients are
assessed as summarized in Additional file 2.
Parents/guardians are encouraged to return to the
clinic for follow-up assessments on days 3, 7, 14, 21 and
28, and on any unscheduled day if the child is not well.
Post- randomized controlled trial phase
All patients included in the RCT phase and presenting a
clinical or parasitological failure from day 14 onwards
are retreated with the country’s first-line treatment (AL
or ASAQ). We expect about 50 patients per site to par-
ticipate in this phase. All patients are followed up exactly
as during the RCT and study procedures are also identi-
cal. In case of confirmed failure before day 14, patients
are treated with the first-line ACT and excluded from
further follow-up. The same procedures are followed for
each repetitive treatment failure occurring between 14
and 28 days after each treatment course. The liver func-
tion and hematologic parameters are monitored in par-
ticipants exposed to three ASAQ courses or more.
Patient selection
Inclusion criteria for the pre-randomized controlled trial
phase
In order to be eligible, patients should satisfy the follow-
ing inclusion criteria:
1. Males and females aged between 12 months and 59
months inclusively. This criterion applies only for
the recruitment in the first follow-up. For the
subsequent follow-up, children included in the first
follow-up are eligible, regardless of their age.
2. Body weight of 9 kg and above.
3. Microscopically confirmed, mono-infection of P.
falciparum or mixed infection containing P.
falciparum (parasitaemia ≥ 2,000/μL to 200,000/μL).
4. Fever (tympanic temperature ≥ 38.0°C) or history of
fever in the previous 24 hours.
5. Hemoglobin value ≥ 6.0 g/dl.
6. Signed (or thumb-printed and witnessed by an
impartial witness whenever parents/guardians are
illiterate) informed consent by the parents or
guardians. Note the first informed consent will be
asked at recruitment in the pre-RCT phase and it
will cover the first 42 days follow-up. The second
informed consent will be asked for at enrolment for
the randomized trial and will cover the remaining
period of the study.
7. Parents’ or guardians’ willingness and ability to comply
with the study protocol for the duration of the study.
Exclusion criteria for the pre-randomized controlled trial
phase
Patients with at least one of the following criteria will be
excluded:
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1. Participation in any other investigational drug study
(antimalarial or others) during the previous 30 days.
2. Known hypersensitivity and previous serious adverse
events (SAEs) related to the study drugs.
3. Severe malaria [15] or danger signs: not able to
drink or breast-feed, vomiting (more than twice in
24 hours), recent history of convulsions (more than
once in 24 hours), unconscious state, unable to sit
or stand.
4. Presence of intercurrent illness or any condition
(cardiac, renal, hematologic, hepatic diseases) which
would place the subject at undue risk or interfere
with the results of the study, including known
glucose-6-phosphate dehydrogenase deficiency.
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AL 3 days
Quinine+clindamycine 7 days
Clinical treatment failure between
day 14 and day 42*
124+124+62
Participants/site*
Failure before day 14
No (clinical or parasitological)
Failure at day 28
(Clinical or parasitological)
treatment failure between
day 14 and day 28**
1st Line treatment (AL or ASAQ)
during 3 days
Approx. 60
Participants/site*
Approx. 10
Participants/site*
Approx. 2
Participants/site*
Failure before day 14
No Failure at day 28
(Clinical or parasitological)
treatment failure between
day 14 and day 28**
1st Line treatment (AL or ASAQ)
during 3 days
Failure before day 14
No Failure at day 28
(Clinical or parasitological)
treatment failure between
day 14 and day 28**
1st Line treatment (AL or ASAQ)
during 3 days
Failure before day 14
No Failure at day 28
?
Figure 1 Study design flow chart. ACT, artemisinin-based combination therapy; AL, artemether-lumefantrine; ASAQ, artesunate-amodiaquine;
RCT, randomized controlled trial.
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5. Patients who are taking drug which may prolong the
QT interval on the electrocardiogram (imidazole
and triazole, antifungal agent).
6. Severe malnutrition (defined as weight for height
<70% of the median National Center for Health
Statistics/WHO Toxicity Grading Scale for
Determining the Severity of Adverse Events).
7. Ongoing prophylaxis with drugs having antimalarial
activity such as cotrimoxazole for the prevention of
Pneumocistis carinii pneumonia in children born to
HIV+ women.
Inclusion criteria for the randomized controlled trial
phase
1. Have been enrolled in the first phase
2. Recurrent P. falciparum infection with clinical
symptoms (this could be either mono or mixed
infections).
3. Parents’ or guardians’ willingness and ability to
comply with the study protocol for the duration of
the study.
4. Signed (or thumb-printed whenever parents/
guardians are illiterate) (second) informed consent
by the parents or guardians. Note, the informed
consent will cover the whole period of the study,
including additional active follow-ups.
Exclusion criteria for the randomized controlled trial
phase
Patients with any of the following criteria will not be ad-
mitted to the study:
1. Known hypersensitivity or serious drug-related
adverse event (AE) to the study drugs.
2. Severe malaria.
3. Danger signs: not able to drink or breast-feed,
vomiting (more than twice in 24 hours), recent
history of convulsions (more than once in 24 hours),
unconscious state, unable to sit or stand.
4. Treatment failure within 14 days in the first study
phase.
5. Body weight below 9 kg.
Endpoints
Primary endpoint
The primary endpoints are: (1) PCR-adjusted efficacy at
28 days: the proportion of children with PCR adequate
clinical and parasitological response (ACPR) at day 28;
and (2) all early failures before day 7 plus the recurrent
parasitemias detected later and classified by genotyping
as recrudescence. The treatment failure is defined
according to the WHO criteria [16] as the sum of early
treatment failures (ETFs) and late treatment failures
(LTFs) (Table 1).
The ACPR is defined as absence of parasitemia at the
end of the follow-up period (day 28), irrespective of tym-
panic temperature without previously meeting any of the
criteria of ETF or LTF. In the PCR-adjusted analyses, pa-
tients with late asexual parasite reappearance (with or
without fever) will be considered ACPR if the PCR ana-
lysis shows a new infection rather than a recrudescence.
Secondary efficacy endpoints
1. PCR-unadjusted efficacy at 28 days - the proportion
of children without (PCR not adjusted) treatment
failure; all treatment failures detected during the
active follow-up, regardless of genotyping.
2. Clinical efficacy at 42 days - all clinical treatment
failures detected during the 42 days follow-up for
the first-line treatment, with and without PCR
Table 1 Definition of early and late treatment failures
Early treatment failure (one of the following) Late treatment failure
(i) Development of danger signs or severe
malaria on day 0, day 1, day 2 or day 3, in the presence of parasitemia
Late treatment failure is divided into
late clinical and late parasitological failure
(ii) Parasite density on day 2 > day 0 count,
irrespective of tympanic temperature
Late clinical failure:
(iii) Presence of parasitemia on day 3 with
fever (tympanic temperature ≥ 38.0°C)
(i) Development of danger signs or severe
malaria after day 3 in the presence of parasitemia
(iv) Parasitemia on day 3 ≥ 25% of count on day 0 (ii) Presence of parasitemia and fever on any day
from day 4 to day 28, without having
previously met the criteria of early treatment failure
Late parasitological failure:
Parasitemia after day 3 in the absence of fever
(tympanic temperature <38.0°C) and without
having previously met the criteria of early
treatment failure or late clinical failure
The treatment failure is defined according to the World Health Organization criteria [16] as the sum of early and late treatment failures.
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adjustment. As no active monitoring of parasitemia
after day 3 is planned, this includes ETF and late
clinical failure (LCF) following WHO criteria.
3. Fever clearance time - defined as the time (in days)
from the time of randomization to the first two
consecutive measurements on 2 different days of
tympanic temperature below 38.0°C.
4. Asexual parasite clearance time - defined as the time
(in days) from time of randomization to 2
consecutive negative blood slides (collected at
different days). The time to the event will be taken
as the time to the first negative slide.
5. Gametocytemia (prevalence and density) at days 7,
14, 21 and 28 after treatment.
6. Hemoglobin changes between day 0 and days 14
and 28.
Tertiary efficacy endpoints
Tertiary efficacy endpoints will be defined in the substudy
protocols.
Safety endpoints
Subjects will be monitored throughout the study for
possible development of AEs. All AEs will be recorded
on the specific form in the case report form (CRF). Vital
signs and hematology will be monitored and changes in
relevant laboratory parameters will be assessed.
PCR analysis
PCR plays a key role as it determines if recrudescence
will be eliminated after retreatment with the first-line
ACT (Figure 2). Blood samples collected on filter paper
for PCR genotyping will be analyzed at the Institute of
Tropical Medicine, Antwerp, Belgium. Samples will be
collected according to the study-specific standard oper-
ating procedures.
Genotyping
Genotyping of the recurrent infections will be done by char-
acterizing msp1, msp2 and glurp genes in the P. falciparum
genome. PCR amplification of DNA from a single para-
site clone results in a single amplification product. For
the three genes, each PCR amplification product of a
different size is considered to originate from a different
clone of P. falciparum and reflects a different genotype.
For the samples collected from the same patient at day
0 and on the day of recurrent parasitemia, the length
polymorphism of msp1, msp2 and glurp will be
determined (that is the number of bands in each PCR
reaction and their respective size). Results will be
interpreted as follows: recrudescence (for each marker
(msp1, msp2 and glurp), at least one identical length
polymorphism is found in the sample collected at day 0
and on the day of recurrent parasitemia); new infection
(for at least one marker, length polymorphism is differ-
ent between the sample collected at day 0 and that on
the day of recurrent parasitemia); indeterminate (samples
Uncomplicated malaria ETF
New infection
1st line ACT treatment 
Quinine+clindamycin
New infection
Recrudescence
ASAQ/ AL/ Quinine+ 
clindamycin treatment
No recrudescence
Figure 2 Role of molecular biology. ACT, artemisinin-based combination therapy; AL, artemether-lumefantrine; ASAQ, artesunate-amodiaquine;
ETF, early treatment failure.
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that failed to produce a result due to an inability to amp-
lify DNA at day 0 and/or on the day of recurrent
parasitemia).
Frozen serum samples
Frozen serum samples are stored on site at -70°C or at
the sponsors premises until transferred for analysis if a
research protocol adjacent to this study has been ac-
cepted by the relevant Ethics Committee.
Sample size
Assuming the true PCR-corrected efficacy at 28 days of
retreatment with the same ACT is 95%, a sample size of
248 patients (that is, 124 per site) is needed to show with
80% power that the lower 95% confidence interval of the
efficacy of retreatment with the same ACT should be
90%.
Based on the non-inferiority design, recruiting the
same number of patients on the alternative ACT (that
is, AL in DRC and ASAQ in Uganda) and half on
quinine + clindamycin will allow the estimation of the
relative risk in efficacy between the treatment groups to
be within 5% assuming a similar efficacy of 95% for all
three treatment groups (with the lower 95% confidence
interval of the efficacy being 90%).
To allow for up to 15% drop-outs or non-evaluable pa-
tients, we will recruit 357 patients in each site. The 2:2:1
allocation ratio is chosen to reduce the number of pa-
tients randomized to the more demanding quinine +
clindamycin treatment regimen. In addition, this allows
greater precision for the documentation of the efficacy
and safety of ACT regimens as a second line, rather than
the standard rescue treatment quinine + clindamycin.
However, the inclusion of the quinine + clindamycin
arm is necessary as a benchmark for assessing the effi-
cacy of the ACT as a second line and an internal
consistency check of the study.
In DRC, the most recent study results [17] on the clin-
ical efficacy of ASAQ in the Equator Province in 2004
show a PCR-uncorrected clinical failure rate of 41% at
day 28. However, in Kinshasa, due to a lower reinfection
incidence, the PCR-uncorrected clinical failure rate can
be expected to be lower at approximately 25%. Assum-
ing a clinical failure rate of 25% and assuming that 80%
of failing patients would be eligible for the RCT and
their guardians provide informed consent, we will need
1,800 children to be enrolled for the initial phase of the
study in DRC to obtain 310 patients recruited in the
clinical trial.
In Uganda, most recent study results on the clinical ef-
ficacy of AL in Mbarara in 2005 show a PCR-unadjusted
clinical failure rate of 23% after 28 days of follow-up
[18]. Empirically, expecting a clinical treatment failure
rate of 25% (assuming a loss to follow-up of 10% and
assuming that 80% of the failing patients would be eli-
gible for the RCT after their guardians have provided in-
formed consent) we will need 1,800 children to be
enrolled for the initial study phase in Uganda to obtain
310 patients recruited in the clinical trial.
The recruitment will continue in each country until
the required sample size in the RCT phase is reached. If
recruitment rates in the RCT are lower than expected,
the study may be extended to additional research sites.
Treatment administration
The study treatment is administered under the direct
supervision of a study nurse. If a patient fails to return to
the clinic in a timely manner for their daily dose of study
drug, they are visited at home and brought to the clinic
the same day. If a patient misses any dose of study drugs,
they are not excluded from the study. The study nurse re-
cords the date and time that study drugs are administered.
Study drugs are given to young children as specified by
the manufacturer of each product. After drug administra-
tion, patients are kept for 60 minutes in the clinic. A dose
is repeated in full if vomiting occurs within 30 minutes of
administration, and in half if vomiting occurs between 30
and 60 minutes. If vomiting persists beyond two add-
itional doses, the patient is withdrawn from the study and
treatment changed.
Concomitant therapies
Disallowed concomitant drug therapies during the active
follow-ups
Any antimalarial or antibiotic with antimalarial activity
(for example, erythromycin or other macrolides, co-
trimoxazole or other sulfonamides, and so forth) are
disallowed. A list of drugs having antiplasmodium activ-
ity was provided to the study clinicians.
Allowed concomitant drug therapies
During the trial, patients can be prescribed drugs such
as paracetamol and antibiotics with no known antimalar-
ial activity (penicillins, cephalosporins). The dose, route,
time and duration of any concomitant medical treatment
is recorded in the CRF.
Special conditions
Parents or guardians are discouraged from obtaining
drugs from any other source such as private pharmacies,
markets or clinics. Parents/guardians are encouraged to
bring their children to the study clinic if they are unwell
or if they are worried about their health.
Rescue treatments
All patients who develop severe malaria during follow-
up are treated following National Guidelines. Patients
randomized to ACT and experiencing treatment failure
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before 14 days are treated with quinine 10 mg/kg orally
three times a day in combination with clindamycin 10
mg/kg twice daily for at least 5 days. Patients who fail
with quinine + clindamycin therapy are treated with the
first-line therapy (ASAQ or AL).
Patient withdrawal criteria
Patients will be excluded from further assessment if there
is withdrawal of informed consent. SAEs related to the
study drug are also a reason for withdrawal from the
study. Intake of disallowed drugs leads to withdrawal of
the patient from active follow-up. Participants also may be
withdrawn if the study sponsor, government or regulatory
authorities, or site Ethics Committee terminate the study
prior to its planned end date. Every reasonable effort will
be made to complete a final evaluation of participants who
terminate from the study prior to the planned termination
time period and study staff will record the reason(s) for all
withdrawals from the study in participants’ study records.
At the time of withdrawal, all study procedures outlined
for the end of study visit are completed. The primary rea-
son for a patient’s withdrawal from the study is to be
recorded in the source documents.
Protocol violations
A protocol violation occurs when an event happens that
does not allow for accurate interpretation of response to
treatment. Protocol violations will be defined in the stat-
istical analysis plan.
Safety variables
Safety and tolerability of the treatments will be evaluated
by recording AEs and grading laboratory, and vital sign
evaluations.
Adverse events
At each visit, the investigator will ascertain the occur-
rence of any AE since the last visit. Any event must be
recorded on the CRF.
Definition of an adverse event
An AE is any untoward medical occurrence in a patient
or clinical investigation subject administered a pharma-
ceutical product and which does not necessarily have a
causal relationship with this treatment. An AE can
therefore be any unfavorable and unintended sign (that
could include a clinically significant abnormal laboratory
finding), symptom or disease temporally associated with
the use of a medicinal product, whether or not consid-
ered related to the medicinal product.
Examples of an AE include:
1. Significant or unexpected worsening or exacerbation
of the condition under study.
2. Exacerbation of a chronic or intermittent pre-
existing condition including either an increase in
frequency and/or intensity of the condition.
3. New conditions detected or diagnosed after
investigational product administration even though it
may have been present prior to the start of the study.
4. Signs, symptoms, or the clinical sequelae of a
suspected interaction.
5. Signs, symptoms, or the clinical sequelae of a
suspected overdose of either investigational product
or a concurrent medication (overdose as such
should not be reported as an AE/SAE).
6. Significant failure of expected pharmacological or
biological action.
Examples of an AE do not include:
1. Situations where an untoward medical occurrence
did not occur (social and/or convenience admission
to a hospital).
2. Anticipated day-to-day fluctuations of pre-existing
chronic disease(s) or condition(s) present or detected
at the start of the study that do not worsen.
Severity, relationship of event to study drug, and
outcome
The severity of a clinical AE is to be scored according to
the following scale:
1. Mild: awareness of sign or symptom, but easily
tolerated
2. Moderate: discomfort enough to cause interference
with usual activity
3. Severe: incapacitating with inability to work or
perform usual activity
4. Life-threatening: patient at risk of death at the time
of the event
Assessment of causality
The investigator is obliged to assess the relationship be-
tween the investigational product and the occurrence of
each AE/SAE. The investigator will use clinical judgment
to determine the relationship. Alternative causes, such
as natural history of the underlying diseases, concomi-
tant therapy, other risk factors, and the temporal rela-
tionship of the event to the investigational product will
be considered and investigated. The investigator will also
consult the drug information and the Data Safety and
Monitoring Board (DSMB) as needed in the determin-
ation of their assessment.
There may be situations when an SAE has occurred and
the investigator has minimal information to include in the
initial report to the Trial Management Group (TMG).
However, it is very important that the investigator always
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make an assessment of causality for every event prior
to transmission of the SAE report to the TMG. The
investigator may change their opinion of causality in light
of follow-up information, amending the SAE CRF
accordingly.
The relationship of an AE to study drug is to be
assessed according to the following definitions:
1. Definitely unrelated: should be reserved for those
events which occur prior to test drug administration
(for example, washout or single-blind placebo) or for
those events which cannot be even remotely related
to study participation (for example, injury caused by
a third party).
2. Unlikely: there is no reasonable temporal association
between the study drug and the suspected event and
the event could have been produced by the subject's
clinical state or other modes of therapy administered
to the subject.
3. Possible: the suspected AE may or may not follow a
reasonable temporal sequence from study drug
administration but seems to be the type of reaction
that cannot be dismissed as unlikely. The event
could have been produced or mimicked by the
subject's clinical state or by other modes of therapy
concomitantly administered to the subject.
4. Probable: the suspected AE follows a reasonable
temporal sequence from study drug administration,
abates upon discontinuation of the drug, and cannot
be reasonably explained by the known
characteristics of the subject's clinical state.
5. Definitely related: should be reserved for those
events which have no uncertainty in their
relationship to test drug administration. This means
that a rechallenge was positive.
The outcome of each AE must be assessed according
to the following classification:
1. Completely recovered: the patient has fully
recovered with no observable residual effects.
2. Not yet completely recovered: improvement in the
patient’s condition has occurred, but the patient still
has some residual effects.
3. Deterioration: the patient’s overall condition has
worsened.
4. Permanent damage: the AE has resulted in a
permanent impairment.
5. Death: the patient died due to the AE.
6. Ongoing: the AE has not resolved and remains the
same as at onset.
7. Unknown: the outcome of the AE is not known
because the patient did not return for follow-up
(lost to follow-up).
Definition of a serious adverse event
An SAE or reaction is any untoward medical occurrence
that at any dose fulfils at least one of the following
criteria:
 Results in death.
 Is life-threatening. (Note that the term 'life-
threatening' in the definition of 'serious' refers to an
event in which the subject was at risk of death at
the time of the event. It does not refer to an event,
which hypothetically might have caused death, if it
were more severe.)
 Requires hospitalization (other than for drug
administration) or prolongation of existing
hospitalization. (Note that, in general,
hospitalization signifies that the subject has been
detained (usually involving at least an overnight
stay) at the hospital or emergency ward for
observation and/or treatment that would not have
been appropriate in the physician’s office or
outpatient setting. Complications that occur during
hospitalization are AEs. If a complication prolongs
hospitalization or fulfills any other serious criteria,
the event is an SAE. When in doubt as to whether
'hospitalization' occurred or was necessary, the event
should be considered an SAE. Hospitalization for
elective treatment of a pre-existing condition that
did not worsen from baseline is not considered an
AE, nor hospitalization for non-medical reasons
(for example, the patient stays at the hospital
overnight because they live too far and/or there
is no transport).)
 Results in persistent or significant disability/
incapacity. (Note that the term disability means a
substantial disruption of a person’s ability to conduct
normal life functions. This definition is not intended
to include experiences of relatively minor medical
significance such as uncomplicated headache,
nausea, vomiting, diarrhea, influenza, and accidental
trauma (for example, sprained ankle) which may
interfere or prevent everyday life functions but do
not constitute a substantial disruption.)
Medical or scientific judgment should be exercised in
deciding whether reporting is appropriate in other situa-
tions, such as important medical events that may not
be immediately life-threatening or result in death or
hospitalization but may jeopardize the subject or may re-
quire medical or surgical intervention to prevent one of
the other outcomes listed in the above definition. These
should also be considered serious. Examples of such
events are invasive or malignant cancers, intensive treat-
ment in an emergency room or at home for allergic
bronchospasm, blood dyscrasias or convulsions that do
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not result in hospitalization, or development of drug de-
pendency or drug abuse.
All SAEs, whether or not deemed drug-related or
expected, must be reported immediately or within 24
hours (one working day), using the Serious Adverse Event
Notification Form, by telefax to +32-2652875 or email to
international.health@ua.ac.be (International Health Unit,
Department of Epidemiology and Social Medicine,
University of Antwerp, Universiteitsplein 1, BE-2610 Ant-
werp Wilrijk). The fax should state “Urgent Serious Ad-
verse Event” and the study code on the cover page. All
other AEs not fulfilling the criteria of immediate reporting
must be recorded on the CRF. This AE information will be
collected on a regular basis during the clinical trial.
Reporting of adverse events
For all AEs identified, an AE form is completed. For
each possible AE identified and considered as serious, an
SAE event notification form is completed.
A severity grading scale, based on toxicity grad-
ing scales developed by the WHO and the National
Institutes of Health, Division of Microbiology and
Infectious Diseases, is used to grade severity of all
symptoms, physical examination findings, and hemoglobin
results (Guidelines for Grading Patient Symptoms,
signs and laboratory findings). Any new event, or an
event present at baseline that is increasing in sever-
ity, will be considered as an AE.
Length of follow-up for adverse events
For AEs presenting during the study, a patient still ex-
periencing an AE at the end of a follow-up (that is at
day 42 or 28) will be managed as follows:
– If the AE has been detected and reported before the
last visit and
○ it is mild (grade 1), the patient will be managed
according to good medical practice and the
active follow-up will be stopped. The end date
for the AE will be recorded as day 28.
○ its grade is more than 1, the patient will be
followed until the AE resolves, improves, or
stabilizes.
– If the AE is new, the AE will be reported and the
patient will be followed until the AE resolves,
improves, or stabilizes.
For patients classified as clinical treatment failures
(ETF/LCF/late parasitological failure (LPF)), formal study
follow-up ends when a patient is classified as a treatment
failure (ETF or LTF/LPF), and patients should be treated
and managed according to good medical practice. Add-
itional follow-up for AEs in patients classified as treatment
failures is not typically indicated, unless the AE is serious,
or is felt to be probably or definitely related to the study
medications.
For patients with SAEs, any patient who experiences
an SAE should be followed until it resolves or improves
(< grade 1). Although formal study follow-up is typically
terminated when a patient is classified as a treatment
failure, any patient with severe malaria/danger signs
should be followed up to ensure their SAE has resolved/
improved.
Laboratory evaluations
Blood samples are properly labeled with patients' initials,
site number, study number, the study day and the date the
sample is taken. Hematology assessments are performed
locally at sites. All laboratory results are reported in
Standard International Units or in conventional units.
Blood samples collected on filter paper for PCR genotyp-
ing will be analyzed at the Institute of Tropical Medicine,
Antwerp, Belgium.
Case report form
All data and observations must be initially documented
in the CRF or copied from source documents to the
CRF (in other words, laboratory data). For this study we
will use DATAfax (Datafax Incorporation, Texas, The
Unated States of America).
Monitoring and quality assurance
The Sponsor will share monitoring and quality assurance
with the Amsterdam Institute for Global Health and
Development based in Uganda. An agreement was
signed to this effect. The task of the monitor is to verify
the best conduct of the study through frequent contacts
by phone and in person with the Principal Investigator
and site staff, in accordance with the Standard Operating
Procedures and Good Clinical Practice, with the pur-
poses of facilitating the work and attaining the objectives
of the study. These visits enable the monitor to maintain
current, personal knowledge of the study through review
of the records, comparison with source documents, ob-
servation and discussion of the conduct of the study
with the investigator. Each site will be visited at least five
times during the conduct of the trial, including a pre-
study visit and a close-out visit. At each visit, the moni-
tor carries out at least 30% source data verification on
the first phase of the study (pre-RCT phase) and 30%
source data verification on the second phase of the study
(RCT and post-RCT phase); however, these percentages
might be increased in case of serious or systematic find-
ings during the monitoring visits. The investigator shall
maintain source documents for each patient in the study,
consisting of case and visit notes (hospital or clinic med-
ical records) containing demographic and medical infor-
mation, laboratory data, and the results of any other tests
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or assessments. The data on the CRF shall be either the
source or traceable to the source documents in the pa-
tient’s file. The investigator shall keep one copy of the ori-
ginal informed consent form signed by the parent/
guardian (the other will remain with the parent/guardian).
The investigator shall give the monitor, auditors, inspec-
tors, Institutional Review Board, and Ethics Committee
full access to all relevant source documents to confirm
their consistency with the CRF entries.
Data management
The Infectious Diseases Institute in Uganda is in charge of
centralized data management. Clinical data, as explained
above, are collected and recorded on appropriate paper
CRF. Laboratory data, as requested in the protocol, are
registered at the laboratory and recorded onto the CRF.
All data are then processed from the CRFs into an elec-
tronic database. During the conduct of the study, data are
verified and reviewed to produce and maintain high-
quality data. All unresolved issues are queried and re-
solved on a regular basis. Data transfer and handling is
done with appropriate security measures and with regard
to rights, safety and well-being of trial subjects. A report
on data management processes will be produced at study
completion. The report will include a full field listing and
description of the file structure of the electronic data:
– Reference ranges and units for laboratory data
– A brief description of all programs run on the data
– Level of errors found at each stage of checking the data
– General comments on data quality and significant
problems encountered with the data
– A detailed list of any unresolved data queries
– A statement of any queries/errors which have not
been corrected on the database
– A statement of the storage location of the electronic
database
The statistician will review the database prior to
finalization and report on any problem encountered dur-
ing the analysis.
Statistical analysis
A detailed analysis plan will be drawn up prior to the ana-
lysis. The statistical analysis of the study will be performed
by the DRC Principal Investigator (PI), Dr Hypolite
Muhindo Mavoko, in consultation with statisticians at
the Institute of Tropical Medicine and/or University
of Antwerp, who will also review the analysis plans and
analysis results.
Baseline comparability
Children in the treatment groups in each country will be
described separately with respect to baseline characte-
ristics. The clinical importance of any imbalance will be
noted, although statistical tests of significance will not
be undertaken.
Efficacy analyses
Primary
The primary hypothesis of the study is that the PCR-
adjusted efficacy at 28 days of retreatment with the same
ACT is at least 90%. This hypothesis will be tested by
constructing a two-sided 95% confidence interval for the
proportion of children without PCR-adjusted rescue treat-
ment failure. If the 95% confidence interval lies entirely
above 90% the hypothesis is accepted.
The confidence interval will be constructed using
Wilson's score method, pooling the data from the two
countries (that is, ASAQ treatment group in DRC and
AL treatment group in Uganda).
In addition, the relative efficacy of the retreatment with
the same ACT compared to treatment with quinine +
clindamycin and treatment with another ACT will be
assessed using log-binomial models [19] with fixed effects
for treatment group and country. From this model, the
relative risks of treatment success will be estimated to-
gether with their 95% confidence interval. Appropriate-
ness of pooling the results over the two countries will be
assessed by testing country-by-treatment interactions in
this log-binomial model.
For the efficacy analysis, both an intention-to-treat
and a per-protocol approach will be adopted, with the
intention-to-treat analysis being the primary approach.
Rules for inclusion/exclusion of children from the per-
protocol population will be specified in advance.
Secondary analyses
Statistical methods for secondary analyses will be de-
scribed in the data analysis plan.
Every effort will be made to minimize the amount of
missing data in the trial. Whenever possible, information
on the reason for missing data will be obtained. Sensitiv-
ity analyses will be undertaken to assess the robustness
of the conclusions to the missing data.
Safety analyses
All non-serious and SAEs will be grouped according to a
pre-specified side-effect coding system and tabulated for
each treatment group. In contrast to the primary efficacy
analysis, actual treatment groups will be assessed.
The number (and percentage) of patients experiencing
any AE, SAE, or drug-related SAE will be compared
between treatment groups using Fisher's exact test.
Safety will be analyzed using the all-patients-treated
approach. Data analysis will be primarily performed
using STATA statistical software packages (Stata Corp,
Lakeway, College Station, Texas, USA). Descriptive
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statistics will be used to summarize baseline characteris-
tics of study patients. Efficacy and safety data will be
evaluated using a modified intention-to-treat analysis
and will only include patients who meet all selection cri-
teria. Categorical variables will be compared between the
treatment groups using odds ratio, chi-square tests or
Fisher’s exact tests, and continuous variables will be
compared using t tests or non-parametric tests. A
P value of <0.05 will be considered statistically signifi-
cant. Estimates of the risk of failure for all primary out-
comes will be made using the Kaplan-Meier product
limit formula. Patients excluded after enrollment will be
censored at the time of their last assessment. Addition-
ally, for genotyping adjusted outcomes, patients with
recurrent malaria or recurrent parasitemia due to new
infections will be censored. Stratified analysis shall
be done for outcomes in patients with recurrent
symptomatic (ETF, LCF) and recurrent asymptomatic
(LPF) malaria. The number (and percentage) of patients
experiencing each AE will be compared between the
treatment groups. No formal statistical testing will be
undertaken.
Investigator responsibility
The term "investigator" as used in this protocol and on
the CRFs refers to the PI or a member of the staff that
the investigator designates to perform a certain duty
under this protocol. The investigator is ultimately re-
sponsible for the conduct of all aspects of the study. For
all other relevant investigator responsibilities, see [20].
Administrative procedures
Regulatory authorities and ethical review committee
This protocol has been approved by the Ethical Commit-
tee of the University of Antwerp (Reference: UA A11-02),
the Uganda National Council for Science and Technology
(Reference: HS 1108) and the Ethic Committee of the
School of Public Health, University of Kinshasa (Refer-
ence: ESP/CE/012B/2012).
Informed consent
All interviews are conducted in the native language of
the patients by the study personnel. Consent forms in
the local language are provided to the parents or guard-
ians for their review. The parents or guardians are asked
to sign (or thumb-print whenever the parents/guardians
are illiterate) consent to participate in a research study.
The informed consent describes the purpose of the
study, the procedures to be followed, and the risks and
benefits of participation. If a parent or guardian is un-
able to read or write, an impartial witness takes part in
the informed consent discussion and signs the consent
form. Parents or guardians are informed that participa-
tion in the study is completely voluntary and that they
may withdraw their child from the study at any time
without any negative consequences.
Confidentiality and publication of results
All study documents are provided by the investigators
and their appointed staff. None of this material may be
disclosed to any party not directly involved in the study
without written permission from the investigator. Publi-
cation policy will be addressed in a separate agreement.
Protocol amendments
Clinical protocol amendments are alterations to a legal
document (the clinical protocol) and have the same legal
status and must pass through the appropriate steps be-
fore being implemented. In general, any change must be
prior approved by the Independent Ethics Committee
to be effective. Administrative changes need only notifi-
cation to the Independent Ethics Committee without
approval. Any subsequent amendments shall be made
available with a new protocol with the amendments
incorporated and on separate sheets and must pass
through the approval process.
Insurance
A no-fault liability insurance has been taken by the
Sponsor and covers both trial sites.
Archiving
The relevant study documents are those documents
which individually and collectively permit assessment of
the conduct of the trial, the quality of the data produced
and the compliance with Good Clinical Practice stan-
dards and applicable regulatory requirements. The on-
site file of the PI contains all the essential documents as
listed in the Sponsor’s SOP (Set up and maintenance of
the Investigator Trial File). A copy of all source data and
CRFs must always be kept on site.
The PI is responsible for ensuring a secure and appro-
priate location for their file and any other trial-related
documentation present at site, as well as for ensuring that
only site staff that are competent and delegated to work
for the trial has access to the files. All the relevant study
documentation present at all partners involved should be
retained for a minimum of 5 years and according to the
applicable National Legislation. The Sponsor should al-
ways be informed prior to destruction of the files. After
completion of the study, the investigator’s file will remain
available for internal audits and/or inspections of regula-
tory authorities for a period of 20 years, unless otherwise
requested by national authorities.
Data safety and monitoring board
An independent DSMB with three members (a pediatrician,
a statistician and a malariologist/ epidemiologist) has been
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created before field activities started. The DSMB was
established for the purpose of providing independent advice
on the quality of the data produced and the efficacy
and safety of the treatments tested, so contributing to
safeguarding the interests of the trial participants. More
specifically the DSMB:
 assesses the quality of data, including completeness;
 monitors recruitment figures and loss to follow-up;
 monitors compliance with the protocol by
participants and investigators;
 monitors evidence for treatment differences in the
main efficacy and safety outcome measures, thus
recommending action when/whether the main trial
question has been answered;
 monitors evidence for treatment harm (for example,
toxicity, SAEs, deaths);
 recommends whether the trial should continue to
recruit or follow-up;
 recommends any major changes to the protocol
where necessary (for example, changes to
recruitment procedures, inclusion criteria,
endpoints, data collection, and so forth);
 advises on and/or endorsing any major protocol
modifications suggested by the Trial Steering
Committee (for example, changes to the inclusion
criteria, endpoints, data collection, and so forth);
 monitors planned sample size assumptions;
 suggests additional data analyses;
 assesses the impact and relevance of any external
evidence provided;
 monitors compliance with previous DSMB
recommendations;
 considers the ethical implications of any
recommendations made by the DSMB.
In this respect, the DSMB has the possibility to moni-
tor the safety of the treatment on a continuous basis and
possibly stop the study if any major safety concern ap-
pears. A DSMB charter, where the relevant terms of ref-
erence are clearly defined, has been signed by each
member of the Committee.
Ethical issues
The investigators agreed to conduct the present study in
full agreement with the principles of the “Declaration of
Helsinki” and subsequent relevant amendments. All re-
search activities are run in accordance with the standards
and codes of conduct accepted by the International Con-
ference on Harmonisation guidelines.
AL and ASAQ have been successfully used for the
treatment of falciparum malaria in Phase III studies and
are both widely used to treat uncomplicated malaria in
Africa. The combinations are well tolerated. In DRC,
quinine + clindamycin is the second-line treatment for
malaria. Uganda has not yet adjusted a treatment policy.
The treatment is cheap, widely available and generally
considered to be effective.
Blood is collected for the hematology, biochemistry,
blood slides, and later genotyping and other tests that
the clinician may request. The amount collected for
hemotology and biochemistry is around 3 ml (venous)
while for the other tests the amount is a few drops col-
lected by fingerprick. Residual serum will is separated,
stored and transported at -70°C to be assayed by ELISA
and fluorescence-activated cell sorting for malarial anti-
body quantification (described in an independent proto-
col after the operational part of the study is finished).
Trial status
Active recruitment.
Additional files
Additional file 1: Follow-up chart for the pre-randomized
controlled trial phase.
Additional file 2: Follow-up chart for the randomized controlled
trial phase (and post-randomized controlled trial).
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